Fucicort

Fucicort

betamethasone + fusidic acid

Manufacturer:

LEO Pharma

Distributor:

Getz Bros
Full Prescribing Info
Contents
Fusidic acid, betamethasone valerate.
Description
Each gram of cream contains fusidic acid 20 mg and betamethasone valerate 1 mg in a water-miscible base.
Action
Fusidic acid is a potent topical antibacterial agent. Betamethasone is an anti-inflammatory and antipruritic agent. Concentrations of 0.03-0.16 mcg/mL of fusidic acid inhibit nearly all strains of Staphylococcus aureus, including strains resistant to penicillin or to other antibiotics. Topically applied fusidic acid is also effective against Streptococci, Corynebacteria, Neisseria and certain Clostridia.
Pharmacokinetics: Betamethasone valerate is absorbed through the skin when applied topically. Fusidic acid penetrates normal or inflamed skin and achieves bactericidal concentrations down to the lower corium.
Indications/Uses
Inflammatory dermatoses where bacterial infection is present or likely to occur eg, atopic eczema, discoid eczema, stasis eczema, seborrhoeic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.
Dosage/Direction for Use
Uncovered Lesions: Apply 2-3 times a day. Covered Lesions: Less frequent applications may be adequate.
Overdosage
None.
Contraindications
Viral disease of the skin, perioral dermatitis, acne rosacea, fungal skin infections and ulcerative conditions.
Warnings
Fucicort is not to be used in the eye as there is a potential risk of glaucoma.
Dermal steroids should not be used in large amounts or for prolonged periods of time in pregnancy; foetal abnormalities have been seen in animals due to systemic absorption.
Special Precautions
When steroids, particularly fluorinated steroids are applied for long periods of time (>4 weeks), atrophic striae is likely to occur.
Systemic absorption resulting in adrenal suppression may occur especially under occlusion with weekly doses of >30 g.
Prolonged use on flexures and intertriginous areas should be avoided.
Use in pregnancy: Topical administration of any corticosteroid to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively over long periods.
Use in children: Babies and children up to 4 years should not be treated with dermal steroids for >3 weeks. In infants, the napkin may act as an occlusive dressing and increase absorption. Adrenal suppression is more likely to occur in infants and children.
Use In Pregnancy & Lactation
Use in pregnancy: Topical administration of any corticosteroid to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively over long periods.
Adverse Reactions
Hypersensitivity has rarely been encountered. Adrenal suppression can occur. Prolonged and intensive treatment with highly active corticosteroid preparations may cause local atrophic changes in the skin eg, striae, thinning and dilatation of the superficial blood vessels, particularly when occlusive dressings are used or when skin folds are involved.
Drug Interactions
No relevant information available.
Storage
Store below 25°C.
ATC Classification
D07CC01 - betamethasone and antibiotics ; Belongs to the class of potent (group III) corticosteroids, in combination with antibiotics. Used in the treatment of dermatological diseases.
Presentation/Packing
Cream (white) 5 g.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in